Pyrotinib trials for HER2-positive Breast Cancer

All Pyrotinib trials · All HER2-positive Breast Cancer trials

Phase breakdown

Recruiting trials studying Pyrotinib for HER2-positive Breast Cancer

• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
  NCT06754059 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Pyrotinib in Women With High-risk in Early Stage Breast Cancer
  NCT05834764 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
  NCT06217185 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many trials study Pyrotinib for HER2-positive Breast Cancer?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.